The United States launches a new trade probe into Germany’s pharmaceutical pricing under Section 301 of the Trade Act of 1974, aiming to examine whether Germany’s policies “persistently” underpay for innovative medicines and thereby burden U.S. commerce. Multiple outlets report that the investigation, led by the U.S. Trade Representative, could ultimately result in trade measures, including possible tariffs on German goods, if the U.S. determines Germany’s practices are unfair.
German policy changes are also central to the dispute. Several reports say Berlin is planning health system reforms intended to lower medicine prices and reduce spending, including by cutting costs borne by insurers. The U.S. frames these efforts as contributing to underpayment for innovative drugs, while USTR official Jamieson Greer characterizes the German approach as a “serious step backwards.”
Outlets also note the broader context of a long-running disagreement over how countries share the costs of medical innovation. The probe is described as a mechanism for the U.S. to assess whether U.S. patients and businesses are effectively paying more than their share compared with Germany.
